Komipharm International Co., Ltd.

Total Valuation

Komipharm International Co., Ltd. carries a market capitalization of 549.88B, placing it among publicly traded companies globally. Its enterprise value stands at 618.08B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Valuation Ratios

Komipharm International Co., Ltd. trades at a trailing price-to-earnings ratio of 69.73. The price-to-sales ratio is 12.00, and the price-to-book ratio stands at -62.28.

Enterprise Valuation

On an enterprise value basis, Komipharm International Co., Ltd. trades at an EV/EBITDA multiple of 352.75 and an EV/FCF ratio of 98.52. The EV/Sales ratio of 12.36 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 352.75 provides insight into valuation relative to core operating earnings.

Financial Position

Komipharm International Co., Ltd. maintains a current ratio of 1.31, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 54.85, indicating elevated leverage, while an interest coverage ratio of 0.76 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Stock Price Statistics

Komipharm International Co., Ltd.'s stock has gained approximately 47.6834% over the past 52 weeks. The 50-day moving average sits at 8,277.20, while the 200-day moving average is 7,617.00.

Income Statement

Over the trailing twelve months, Komipharm International Co., Ltd. generated 49.99B in revenue and converted that into -6.40B in net income, yielding earnings per share of -101.48. EBITDA reached 1.75B, while operating income came in at 1.75B.

Balance Sheet

Komipharm International Co., Ltd. holds 24.54B in cash and equivalents against 40.22B in total debt, resulting in a net debt position of 21.04B. Total book value stands at -9.63B, with working capital of 15.98B providing operational flexibility.

Cash Flow

Komipharm International Co., Ltd. produced -1.22B in operating cash flow over the past twelve months. After subtracting -5.20B in capital expenditures, free cash flow totaled -6.43B - equivalent to -90.40 per share.

Margins

Komipharm International Co., Ltd. operates with a gross margin of 33.83, reflecting its pricing power and cost economics. The operating margin of 3.50 and net profit margin of -12.80 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Komipharm International Co., Ltd.'s most recent stock split took place on August 17, 2023 with a 1000000:1100689 split ratio.

Scores

Komipharm International Co., Ltd. posts an Altman Z-Score of 6.29, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.